Table 1 Overview of the main demographic and clinical characteristics of the study sample.
From: Xen 63 versus Preserflo MicroShunt implant in patients with primary open-angle glaucoma
Variable | XEN63 (n = 30) | MicroShunt (n = 30) | pa |
|---|---|---|---|
Age, years Mean ± SD 95%CI | 74,6 ± 9.4 | 72,4 ± 9.9 | 0,398 |
Sex, n (%) Women Men | 12 (40.0) 18 (60.0) | 18 (60.0) 12 (40.0) | 0.1245b |
Race, n (%) Caucasian | 30 (100.0) | 30 (100.0) | 1.000b |
Lens status, n (%) Phakic Pseudophakic | 16 (53.3) 14 (46.7) | 20 (66.7) 10 (33.3) | 0.4296b |
Glaucoma type, n (%) POAG | 30 (100.0) | 30 (100.0) | 1.000b |
Preoperative IOP, mmHg Mean (SD) 95%CI | 20.8 ± 3.6 19.5 to 21.2 | 19.1 ± 3.8 17.7 to 20.5 | 0.0845 |
NOHM, n Mean (SD) 95%CI | 2.3 ± 0.6 2.0 to 2.5 | 2.3 ± 0.7 2.0 to 2.5 | 1.000 |
NOHM, n (%) 1 2 3 | 3 (10.0) 16 (53.3) 11 (36.7) | 5 (16.7) 12 (40.0) 13 (43.3) | 1.000 |
VF damage, dB* MD Mean (SD) 95%CI | −6.5 ± 3.6 −8.2 to −4.9 | −8.1 ± 4.8 −10.2 to 6.0 | 0.2420 |
